Latest Biotech News

UCB will buy Neurona in a deal valued at up to $1.2 billion, positioning the Belgian pharma to broaden beyond its small-molecule epilepsy portfolio with a potentially one-off cell therapy. The...

Revolution Medicines reported a landmark survival benefit for its investigational RAS-targeting drug daraxonrasib (RMC-6236) in a global Phase 3 trial in metastatic pancreatic ductal...

Roche said it will launch a new global Phase 3 trial for the Duchenne muscular dystrophy gene therapy Elevidys after Europe’s main regulator delivered a negative opinion. The company aims to...

Kailera Therapeutics priced an upsized U.S. IPO to raise about $625 million, setting a new benchmark for biotech listings. The obesity-focused company’s offering supports global development across...

Neomorph secured a $100 million Series B financing to advance NEO-811, an oral molecular glue degrader designed to induce targeted degradation of ARNT (HIF-1β). The company plans to use the...

Storm Therapeutics raised $56 million in a Series C financing to support Phase II development of STC-15, an RNA enzyme inhibitor targeting METTL3. The company said it has enrolled the first...

Roche subsidiary Foundation Medicine agreed to acquire Saga Diagnostics for up to $595 million, aiming to expand its oncology diagnostics portfolio in molecular residual disease (MRD). The deal...

Transformative Biotech unveiled extraction-free PCR chemistry designed to remove a key bottleneck in molecular testing workflows, targeting faster and cheaper infectious disease diagnostics. The...

Beeline Medicines launched with a portfolio of five programs licensed from Bristol Myers Squibb, supported by a $300 million Series A led by Bain Capital. The new company is developing afimetoran,...

Grifols said the U.S. FDA approved its Procleix Plasmodium assay for screening blood donors for malaria risk. The automated nucleic acid-based test detects ribosomal RNA sequences from multiple...

Eli Lilly’s oral obesity drug Foundayo cleared a key cardiovascular safety hurdle in people with type 2 diabetes, meeting a primary non-inferiority objective in a heart outcomes study versus...

Kailera Therapeutics raised $625 million in one of biotech’s biggest-ever initial public offerings, topping Moderna’s prior debut record. The Nasdaq offering funds Kailera’s obesity pipeline,...

Revolution Medicines reported positive Phase III results for daraxonrasib (RMC-6236), an orally administered RAS-targeting therapy in metastatic pancreatic ductal adenocarcinoma. In the RASolute...

Beeline Medicines launched with a five-program portfolio in-licensed from Bristol Myers Squibb and backed by a $300 million Series A led by Bain Capital. The company’s lead asset, afimetoran, is a...

MeiraGTx agreed to buy back a failed eye gene therapy from Johnson & Johnson for $25 million upfront, following the therapy’s Phase 3 setback in X-linked retinitis pigmentosa. The transaction...

Grifols won FDA approval for its automated malaria risk screening assay used with the Procleix Panther system. The Procleix Plasmodium Assay is a nucleic acid test for Plasmodium species...

Takara Bio and Resistomap expanded their partnership to develop high-throughput antimicrobial resistance surveillance products from environmental samples. Their SmartChip Biosecurity Platform...

Invivoscribe launched PrepQuant, an extraction-free sample preparation system designed to standardize pre-analytical workflows for molecular testing. The platform integrates nucleic acid...

Ultima Genomics’ ppmSeq platform delivered early TRACERx MRD performance data at AACR, highlighting ultra-sensitive ctDNA detection at low single-digit parts per million in plasma samples. The...

Rice University researchers unveiled electroactive co-culture sensing (e-COSENS), a modular bioelectrical sensor system designed to convert chemical signals into electricity. The technology uses...